OBJECTIVES The aim of this study was to evaluate the cost-effectiveness of drug-coated balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA).
The design and outcomes of the overall IN.PACT SFA trial have been described previously (8, 9) . Briefly, after successful pre-dilation, eligible patients with severe femoral or proximal popliteal stenoses and symptoms of claudication or ischemic rest pain (Rutherford classes II to IV) were randomized in a 2:1 fashion to DCB angioplasty or standard PTA. All patients underwent clinical follow-up, and duplex ultrasound was performed on all patients at 30-day, 6-month, 12-month, and 24-month follow-up.
OVERVIEW OF STUDY DESIGN AND DATA COLLECTION.
The economic analysis was conducted from the perspective of the U.S. health care system. We prospectively collected detailed resource use data for the index hospitalization and all subsequent hospitalizations for vascular care; hospital billing data including summary statements (UB-04 forms) as well as itemized bills were also collected. At baseline and at each follow-up visit through 24 months, quality-of-life assessments were performed using the EuroQol 5-dimensions questionnaire (13) . All clinical endpoints were adjudicated by a blinded clinical events committee.
DETERMINATION OF MEDICAL CARE COSTS.
Medical care costs for the initial hospitalization and through 2-year follow-up were assessed using a combination of "bottom-up" and "top-down" methods as described previously (14) . Given the modest sample size of the study, it was important to limit the scope of the economic analysis to focus on those costs that would Salisbury et al.
be expected to be influenced by the treatment strategy. Thus, the primary cost endpoint was total PADrelated costs for the target limb. OTHER HOSPITAL COSTS. All other hospital costs were determined using "top-down" accounting methods as described previously (15) . Itemized bills were obtained for the initial hospitalization and any subsequent vascular-related hospitalizations during the follow-up period. Hospital costs were determined by multiplying itemized hospital charges by the cost center-specific cost-to-charge ratio obtained from the hospital's Medicare cost report (16 A total of 1,000 independent analyses were performed, and the results are reported in terms of a cost-effectiveness acceptability curve, which describes the probability that DCB angioplasty will be economically attractive (i.e., cost effective) at any societal cost-effectiveness threshold (19) . Salisbury et al. Probabilistic sensitivity analysis demonstrated moderate uncertainty in these results, mainly because of considerable variability in the 2-year cost difference between the 2 treatments ( Figure 2 ). As shown in the cost-effectiveness acceptability curve (Figure 3) , the probability that the DCB angioplasty strategy was economically attractive at a societal willingness-topay threshold of $50,000 per QALY gained was 69.7%. At a more liberal willingness-to-pay threshold of $150,000 per QALY gained, the probability that the DCB strategy was economically attractive was 79.3%. Tables 1 and 2 . Costs were on the basis of estimated sales prices for the various devices and published Medicare reimbursement rates. On the basis of these model inputs, they concluded that from a Medicare perspective, DCB was the lowest cost strategy, followed by DES, standard PTA, and finally bare-metal stent implantation.
RESULTS
Although the results reported by Pietzsch et al. (12) were robust over a range of sensitivity analyses, the study was limited by the need to derive key parameter inputs from small studies including patient Values are % or mean AE SD. Tables 1 and 2 . Values are mean AE SE.
Abbreviations as in
Abbreviations as in Table 1 .
populations that often differed substantially with respect to key variables such as lesion length. Our analyses, the probability that DCB angioplasty would be cost-effective ranged from 58.3% to 63.2% across willingness-to-pay thresholds ranging from £0 per QALY to £100,000 per QALY.
Our study provides several important advantages over these previous studies. Nonetheless, the results of several sensitivity analyses support the robustness of our findings.
Second, we did not examine the cost-effectiveness of other approaches to femoropopliteal angioplasty, such as primary stenting with bare-metal stents or drug-eluting stents or the use of atherectomy devices.
In the absence of head-to-head comparative data between the IN.PACT Admiral DCB and these alternative approaches, however, such comparisons would be speculative at best. Further studies are thus needed to examine the relative costs and cost-effectiveness of these approaches. The results of this study should also not be extrapolated to other DCBs that differ from the The proportion of incremental cost-effectiveness ratio replicates from probabilistic sensitivity analyses that demonstrate economically attractive results across a range of willingness-to-pay thresholds. QALY ¼ quality-adjusted life-year.
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